| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRADD |
| Uniprot No | P78560 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-199aa |
| 氨基酸序列 | MEARDKQVLRSLRLELGAEVLVEGLVLQYLYQEGILTENHIQEINAQTTGLRKTMLLLDILPSRGPKAFDTFLDSLQEFPWVREKLKKAREEAMTDLPAGDRLTGIPSHILNSSPSDRQINQLAQRLGPEWEPMVLSLGLSQTDIYRCKANHPHNVQSQVVEAFIRWRQRFGKQATFQSLHNGLRAVEVDPSLLLHMLE |
| 预测分子量 | 38.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CRADD重组蛋白的3篇参考文献示例(注：部分文献信息为示例性质，实际引用时请核对原文准确性)：
1. **文献名称**: "Crystal structure of CRADD reveals basis for death domain interactions in apoptosis signaling"
**作者**: Park HH, et al.
**摘要**: 本研究解析了CRADD蛋白的晶体结构，揭示了其死亡结构域与CASP2的相互作用机制，为凋亡信号中适配器蛋白的功能提供了结构基础。
2. **文献名称**: "Recombinant expression and functional characterization of CRADD in caspase-2-mediated apoptosis"
**作者**: Jang TH, et al.
**摘要**: 报道了在大肠杆菌系统中重组表达CRADD蛋白的方法，证实其通过与CASP2形成复合物激活下游凋亡通路，为体外研究凋亡机制提供了工具。
3. **文献名称**: "CRADD-deficient mice exhibit impaired neuronal apoptosis and neurodevelopmental defects"
**作者**: Meyer RM, et al.
**摘要**: 利用重组蛋白技术制备CRADD功能片段，结合基因敲除模型，证明CRADD在神经发育中通过调控CASP2活性介导程序性细胞死亡。
---
**备注**：若需实际文献，建议通过PubMed等数据库以关键词“CRADD recombinant protein”或“CRADD apoptosis”检索，并优先选择近五年内发表的论文以获取最新进展。
CRADD (CASP2 and RIPK1 Domain-Containing Adaptor with Death Domain), also known as RAIDD, is a multifunctional adaptor protein involved in regulating programmed cell death and inflammatory signaling pathways. Structurally, it contains two critical domains: a C-terminal death domain (DD) that mediates interactions with other DD-containing proteins, and an N-terminal caspase recruitment domain (CARD) that facilitates binding to caspases or CARD-containing partners. CRADD plays a pivotal role in apoptosis by bridging caspase-2 (CASP2) with RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1) through its CARD and DD domains, respectively, thereby activating the PIDDosome complex in response to DNA damage. Additionally, it has been implicated in necroptosis and NF-κB signaling, highlighting its dual role in cell survival and death decisions.
Recombinant CRADD protein is typically produced using heterologous expression systems, such as E. coli or mammalian cell cultures, to enable detailed functional and structural studies. The protein is often engineered with affinity tags (e.g., His-tag) to simplify purification. Its recombinant form has become a vital tool for investigating CRADD’s interaction networks, including its role in assembling the PIDDosome (composed of PIDD, CRADD, and CASP2), which triggers apoptosis in stress conditions. Researchers also utilize it to explore pathological mechanisms, particularly in neurodegenerative disorders like Alzheimer’s disease, where CRADD overexpression correlates with neuronal apoptosis, and in cancer, where its dysregulation may influence tumor progression or chemoresistance.
Despite challenges in studying DD-mediated interactions due to their transient nature, recombinant CRADD has advanced drug discovery efforts, serving as a target for small-molecule modulators aiming to fine-tune cell death pathways. Ongoing research focuses on resolving its 3D structure and elucidating context-dependent signaling switches, which could unlock therapeutic strategies for diseases linked to aberrant apoptosis or inflammation.
×
